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Figure S1. Levels of CAT, GST and SOD activities and MDA concentrations in experimental groups on day 
15. Comparison was made between the non-infected control (NI), N. ceranae-infected control (I) and groups 
infected and treated with fumagillin from day 1 (I-F1), day 3 (I-F3) and day 6 (I-F6) or A. blazei extract from 
day 1 (I-AB1), day 3 (I-AB3) and day 6 (I-AB6). Group names are indicated in Table 1. Groups labelled with 










Figure S2. Expression levels of immune related genes (abaecin, hymenoptaecin, defensin, apidaecin and 
vitellogenin) in experimental groups on day 15. Comparison was made between the N. ceranae-infected 
control (I) and groups infected and treated with fumagillin from day 1 (I-F1), day 3 (I-F3) and day 6 (I-F6) or 
A. blazei extract from day 1 (I-AB1), day 3 (I-AB3) and day 6 (I-AB6). Group names are indicated in Table 1. 
Groups labelled with the same letter do not differ significantly. The same font style (lowercase or uppercase) 
refer to the same treatment.  
 
 
